Multi-center, Double-blind, Randomized, Placebo-controlled, 5-period, 5-treatment Crossover, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Trial Profile

Multi-center, Double-blind, Randomized, Placebo-controlled, 5-period, 5-treatment Crossover, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs ACT 541468 (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
  • Most Recent Events

    • 13 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 05 Jul 2017 Planned End Date changed from 30 Aug 2017 to 29 Aug 2017.
    • 08 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top